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ABSTRACT
Background
Resistance of malaria parasites to chloroquine (CQ) and sulphadoxine-pyrimethamine (SP) is
increasing in prevalence in Africa. Combination therapy can both improve treatment and
provide important public health benefits if it curbs the spread of parasites harbouring
resistance genes. Thus, drug combinations must be identified which minimise gametocyte
emergence in treated cases, and so prevent selective transmission of parasites resistant to any
of the partner drugs.
Methods and Findings
In a randomised controlled trial, 497 children with uncomplicated falciparum malaria were
treated with CQ and SP (three doses and one dose respectively; n = 91), or six doses of
artemether in fixed combination with lumefantrine (co-artemether [Coartem, Riamet]) (n = 406).
Carriage rates of Plasmodium falciparum gametocytes and trophozoites were measured 7, 14,
and 28 d after treatment. The infectiousness of venous blood from 29 children carrying
P. falciparum gametocytes 7 d after treatment was tested by membrane-feeding of Anopheles
mosquitoes.
Children treated with co-artemether were significantly less likely to carry gametocytes within
the 4 weeks following treatment than those receiving CQ/SP (30 of 378 [7.94%] versus 42 of 86
[48.8%]; p , 0.0001). Carriers in the co-artemether group harboured gametocytes at
significantly lower densities, for shorter periods (0.3 d versus 4.2 d; p , 0.0001) and were
less infectious to mosquitoes at day 7 (p , 0.001) than carriers who had received CQ/SP.
Conclusions
Co-artemether is highly effective at preventing post-treatment transmission of P. falciparum.
Our results suggest that co-artemether has specific activity against immature sequestered
gametocytes, and has the capacity to minimise transmission of drug-resistant parasites.
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An increasing prevalence of drug-resistant parasites now
threatens the efﬁcacy of the antimalarial drugs chloroquine
(CQ), sulphadoxine-pyrimethamine (SP), and amodiaquine
(AQ) in sub-Saharan Africa [1,2,3]. In response, there is
currently a concerted effort to evaluate new combinations of
antimalarials [4]. In addition to direct therapeutic beneﬁts,
there is the important opportunity to select combination
therapy that reduces post-treatment parasite transmission so
as to counteract the selection and transmission advantage of
drug-resistant parasites [4,5,6]. Recently published data show
that the appearance in many geographical locations of
parasites resistant to sulphadoxine and to pyrimethamine is
not necessarily due to multiple de novo events, but rather
that new resistant haplotypes have arisen extremely rarely
and subsequently spread by selection pressure [7]. The goal of
reducing this spread therefore requires that combination
therapy minimises the number of treated individuals har-
bouring gametocytes, the transmissible sexual stages of the
Plasmodium life cycle, and thus does not favour the survival
and transmission of drug-resistant genotypes [8,9]. In a series
of clinical trials in Farafenni, The Gambia, we have evaluated
the effects of combination treatment on the subsequent
infectiousness to mosquitoes of children treated for uncom-
plicated falciparum malaria. Children who received three
daily doses of artesunate (AS) in addition to SP [6] or CQ
[9,10,11] had signiﬁcantly reduced gametocyte carriage and
reduced infectiousness to mosquitoes compared to those who
received either SP or CQ alone. However, the addition of
three doses of artesunate did not wholly prevent gametocyte
emergence in either case, and thus onward transmission
occurred [6,9,10]. As SP-resistant parasites occur in The
Gambia at low frequency [12], and CQ-resistant parasites are
common [8], both SP/AS and CQ/AS will permit the trans-
mission of resistant parasites from treated patients [9,10].
The co-formulation of artemether and lumefantrine,
known as co-artemether (Coartem, Riamet), is an alternative
artemisinin-based combination currently being evaluated in
African clinical trials [13,14]. In areas of drug-resistant
malaria, the World Health Organization (WHO) has recom-
mended that co-artemether be used as a six-dose regimen,
replacing the commonly used four-dose regimen [15,16].
Although no trials of the six-dose regimen have been
reported in Africa, low gametocyte carriage rates have been
observed in efﬁcacy studies using the short treatment course
[13,14]. There have been no studies of the effect of co-
artemether treatment on transmission of parasites to the
mosquito host.
A non-artemisinin combination under consideration in a
number of African countries is CQ/SP, largely due to its low
cost [17]. In The Gambia, where CQ has been front-line
treatment policy up until 2004, clinical treatment failures
with CQ monotherapy are approaching 20% in in vivo tests
of drug efﬁcacy [11]. It is hoped to extend the useful life of
CQ by combining this drug with SP, which retains clinical
efﬁcacy of over 95% in The Gambia [12]. However, both of
these drugs, when used alone, lead to a high prevalence of
gametocyte carriage among treated patients [6,10]. Therefore,
in contrast to artemisinin-based combinations, we are
concerned that CQ/SP will not prevent transmission of CQ-
and SP-resistant parasites from treated cases, resulting in a
rapid deterioration in efﬁcacy.
In this paper we present a study of Plasmodium falciparum
transmission in Gambian children with uncomplicated
malaria who were randomised to receive either six doses of
co-artemether or CQ/SP. The major endpoints presented are
gametocyte carriage rates, peripheral blood gametocyte
density, and infectiousness to Anopheles gambiae mosquitoes
of children carrying gametocytes 7 d after treatment.
Methods
The study design comprised a single-blind, open-label,
randomised, controlled trial in children with acute uncom-
plicated falciparum malaria, who were treated with either a
combination of CQ and SP or six doses of co-artemether.
Major endpoints were post-treatment gametocyte carriage
and infectiousness to mosquitoes of children carrying
gametocytes 7 d after treatment. The study protocol was
approved by both the Joint Gambia Government/Medical
Research Council Ethics Committee and the London School
of Hygiene and Tropical Medicine Ethics Committee (Proto-
col S1) and is wholly compatible with the revised Helsinki
Declaration of 1983 (Protocol S2; Table S1).
Study Children and Treatment
Children 1–10 years of age attending Farafenni Health
Centre, The Gambia, were screened at our recruiting clinic
over a 12-wk period from September to December, 2002.
Children with a temperature greater than 37.5 8C, or a history
of fever and who were blood-ﬁlm positive for P. falciparum at a
density greater than 500 parasites per ll, and for whom
signed informed consent was obtained, were eligible for
recruitment into the study.
Exclusion criteria were: an inability to take drugs orally,
treatment with antimalarial chemotherapy within the past
2 wk, carriage of circulating gametocytes at presentation, any
evidence of chronic disease or acute infection other than
malaria, domicile outside the study area (approximately 10-
km radius), or any signs or symptoms of severe malaria. These
latter included severe anaemia (peripheral blood packed cell
volume [PCV] less than 20%), hyper-parasitaemia (more than
250,000 per ll of peripheral blood), respiratory distress
(respiratory rate over 40 with two of the following: nasal
ﬂaring, intercostal indrawing, subcostal recession, or grunt-
ing), repeated generalized convulsions (three or more per
24 h or two witnessed seizures in 24 h), haemoglobinuria
(dark red/black urine), jaundice, prostration, or circulatory
collapse. Children were randomized to receive co-artemether
or CQ/SP in the ratio 4.5:1 (see below).
Children in the CQ/SP group were given three daily oral
doses of 10 mg of chloroquine base per kilogram of body
weight, plus one half-tablet of SP (12.5 mg of pyrimethamine
with 250 mg of sulphadoxine per half-tablet), and an
additional one-quarter tablet for each 5 kg of body weight
over 10 kg. Children in the co-artemether group received at
each dose one half-tablet of co-artemether (20 mg of
artemether with 120 mg of lumefantrine) per 5 kg body
weight up to 24 kg (two tablets). Children 25 kg or heavier
received the adult dose of three tablets. This treatment was
given six times, at 0 h (i.e., in the clinic at approximately
midday), 8 h (i.e., in the evening of the recruitment day), 20 h,
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treatment. This regimen is consistent with the manufacturer’s
recommendations.
Absorption of co-artemether is facilitated by fatty food, so
the ﬁrst dose was given to all children in both treatment
groups with food (bread with a local oily sauce of beans)
under the supervision of staff at the recruitment clinic. Each
child was observed for 20 min after the ﬁrst dose, and any
child who vomited was administered a full replacement dose.
All subsequent doses of both treatments were administered
by a visiting ﬁeld assistant at the child’s home, accompanied
by food provided by the child’s family.
Each child also received 10 mg/kg paracetamol under
supervision at recruitment, and parents or guardians were
instructed to administer further doses every 6 h until the
child’s symptoms had subsided. Open-label chloroquine
(Alkaloida), pyrimethamine-sulphadoxine (Pharmamed), and
paracetamol (Echo International Services) were used. co-
artemether was purchased from Novartis (Switzerland).
The treatment order was randomised by a Medical
Research Council (MRC) statistician not engaged on the trial,
such that two CQ/SP treatments occurred in each block of 11
assignments (see below). The treatment order, on slips of
paper, was placed in identical envelopes numbered 1 to 550,
each corresponding to a study subject number that was
assigned to a single child by a study clinician prior to opening
of the envelope. All staff engaged in the trial were blinded as
to the treatment group of each child, apart from those in the
recruiting clinic and the ﬁeld assistants responsible for
supervising administration of medication. Trial clinicians
could not inﬂuence the choice of drug given. A physician at
MRC Farafenni, who was not engaged in the study, fulﬁlled
the role of trial monitor and held an additional copy of the
randomised treatment code.
A major endpoint of the trial was infectiousness of patients
to Anopheles mosquitoes, measured 7 d after treatment, so the
study was designed so that approximately equal numbers of
gametocyte carriers would be identiﬁed in both treatment
groups at day 7 of follow-up. The treatment allocation ratio
of 4.5:1 was based on an expected post-treatment day 7
gametocyte prevalence of 40%–50% among children receiv-
ing CQ/SP, as was observed in the previous year (Sutherland
et al., unpublished data), and an estimate of day 7 gametocyte
prevalence among co-artemether-treated children of between
5% and 10% [13,14]. The recruitment of 533 individuals was
expected to provide at least 60 children divided equally
between the two groups who were gametocytaemic on day 7
and prepared to donate venous blood for membrane-feeding,
after gametocyte carriers were excluded at recruitment.
These exclusions were necessary because children who
present with peripheral gametocytaemia are very likely to
carry gametocytes during the post-treatment period and to
be infectious to mosquitoes, independent of the treatment
regimen used [6,10,18]. This sample size would require
dissection of approximately 1,200 mosquitoes. We have
previously found that 5.3% of mosquitoes fed on blood
donated by children treated with CQ/SP and carrying
gametocytes at day 7 became infected, and that 20% of
gametocyte carriers were infectious (Sutherland et al.,
unpublished data). This study was designed to provide a
power of 90% at the 95% conﬁdence level to detect a 3.5-fold
reduction in the proportion of mosquitoes infected by
gametocyte carriers on day 7.
Finger-prick peripheral blood from all children attending
the recruitment clinic was obtained for thick blood-ﬁlm
examination, PCV determination, and, in the case of recruits,
collection of a ﬁlter paper sample for subsequent nucleic acid
extraction. Parasitological admission criteria were checked at
the recruitment clinic using thick blood ﬁlms stained with
rapid Field’s stain; 25 high-power ﬁelds were examined.
Duplicate thick blood ﬁlms from all recruits were returned to
the laboratory, allowed to dry for 24 h, and stained with
Giemsa. Two reads of 100 high-power ﬁelds were performed
for asexual and sexual stage parasites. Parasitaemia was
calculated as described [19].
Transport was provided to bring children to the MRC Field
Station at Farafenni 7 d after treatment to be screened for
circulating gametocytes as previously described [10]. Finger-
prick samples for thick-blood ﬁlm and haematocrit were
obtained, and a ﬁeld assistant ﬂuent in four local languages
posed a ﬁxed list of questions to each guardian and/or child
to determine if clinical signs or symptoms had resolved and if
there had been any of a range of adverse events. Answers were
recorded on a speciﬁc report form designed for this purpose.
Thick-blood ﬁlms were stained with Field’s stain, and 100
ﬁelds were examined immediately for the presence of
gametocytes. Guardians of any gametocyte carriers were
asked if approximately 3 ml of venous blood could be taken
from the child’s arm for membrane-feeding of mosquitoes.
Day 7 follow-up and gametocyte screening were performed
on day 6 in the case of eight individuals for whom day 7 fell
on a religious festival. Children who were not available to be
brought to the MRC laboratory on the morning of day 7 were
followed up at home by a ﬁeld assistant whenever possible,
and the same ﬁxed list of questions posed. However, such
children were not able to be venous blood donors for
mosquito feeding. Field assistants made further visits to each
child on post-treatment days 14 and 28 to obtain ﬁnger-prick
peripheral blood for thick ﬁlms and dried ﬁlter-paper blood
spots for parasite DNA extraction. At each contact with study
participants, ﬁeld staff asked the patient and/or guardians
whether any symptoms indicative of clinical malaria had
persisted or returned since treatment, and whether the child
had experienced any other adverse events. This information
was recorded on a follow-up form. Participants were
encouraged to attend the recruiting clinic at any time should
the child become sick.
Estimating Duration of Gametocyte Carriage
Gametocyte carriage was estimated by scoring each
individual as gametocyte positive or not on each of the
follow-up days (0, 7, 14, or 28) [20]. Given the reported half-
life of gametocytes of 2.5 d [21], a single gametocyte-positive
slide was assumed to represent gametocytes circulating in the
peripheral blood for 2.5 d. When patients had blood ﬁlms
that were gametocyte positive in successive weeks, the
estimated time of gametocyte carriage was the interval
between observations plus 2.5 d. It was assumed that a single
negative or missing slide between two positive slides had a
greater than 50% chance of being positive [22]. Between-
group comparison of mean duration of gametocyte carriage
was by the rank-sum test of Wilcoxon.
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Venous blood samples were obtained from children who
were gametocytaemic (limit of detection, 5 gametocytes/ll) on
day 7, who had a PCV greater than 20%, and whose parent or
guardian gave speciﬁc consent for the procedure. If the
number of gametocyte-positive patients was greater than the
number of cages of mosquitoes available for feeding on a
particular day, consenting gametocyte carriers were selected
in the order in which they were ﬁnger-pricked, which was not
dependent on study identiﬁcation numbers or treatment
group. The mosquito feeds were performed as described
elsewhere [6,10]. In brief, venous blood in citrate-phosphate
dextrose (anticoagulant) was centrifuged and the plasma
removed. After being washed, the red blood cell pellet was
resuspended to a PCV of 33% in pooled type AB serum from
European donors with no history of malaria exposure. This
allowed us to reduce the possible effects of residual drug or of
antibody in the blood meal [10], although some CQ may be
carried over within erythrocytes. Each suspension then was
fed to approximately 50 5-d-old female A. gambiae s.s.
mosquitoes via an artiﬁcial membrane attached to a water-
jacketed glass feeder maintained at 37 8C. Mosquitoes were
from an established colony maintained by feeding on rabbits.
Mosquito mid-guts were dissected 7–8 d later, and the
number of malaria oocysts on the mid-gut recorded.
Molecular Genotyping
P. falciparum genotypes circulating in children with detect-
able asexual parasitaemia during post-treatment follow-up
were compared with those present in the same child prior to
treatment. DNA was extracted from dried blood spots using a
Chelex-based method [8]. Alleles of the polymorphic locus
pfmsp2 were compared between pre- and post-treatment
parasite isolates by PCR [8,23]. The procedure of Cattaman-
chi et al. [24] was followed, in that indeterminate samples in
which a majority of novel bands appeared in the post-
treatment infection were scored as new infections. There
were only seven such indeterminate infections among the 44
successfully typed.
Data Analysis
Data were analysed using Stata, version 8 (StataCorp,
Texas). Proportions were compared using the chi-square
statistic or Fisher’s exact test. In the case of mosquito
dissection data, the conﬁdence intervals (CIs) of proportions
were estimated by bootstrapping to take account of clustering
within feed-cages. Normally distributed continuous variables
were compared using the t-test of Student.
Gametocyte density was compared between groups using
the ratio of arithmetic means, as in a previous study [10]. This
was done by ﬁtting generalized linear models with a
logarithmic link function (the ‘‘nbreg’’ command in Stata),
i.e., modelling the logarithm of the (arithmetic) mean
gametocyte density [25]. Ratios of mean densities were
obtained by exponentiating the relevant regression coefﬁ-
cients. We favour this approach because the test statistic
(mean ratio) is intuitively simple, the negative binomial
function gives a good ﬁt to the typically skewed distributions
observed, and because all data points (including zeroes) are
included. Thus differences in gametocyte prevalence, as well
as density, contribute to the mean ratio.
Results
Of 3,167 febrile children, 1,328 were infected with micro-
scopically-conﬁrmed P. falciparum and did not have circulat-
ing gametocytes. Eighty-three children (6.3%) harboured
both gametocytes and trophozoites, and were not recruited.
A total of 497 eligible children were enrolled in the trial and
randomised between the treatment groups. This was a smaller
number than predicted, because of lower rainfall than in
previous seasons, and thus reduced malaria transmission. The
reason for ineligibility was recorded for 82% of non-recruits.
These were: residence outside the study area (26.1%), para-
sitaemia below the threshold (16.5%), consent withheld
(15.9%), anaemia (PCV below 20%) (7.6%), participation in
another research study (4.4%), recent antimalarial use (3.8%),
hyperparasitaemia (2.9%), other signs of severe malaria
(1.6%), vomiting (0.7%), other disease present (0.6%) and
other reasons not included in the above (19.9%).
Ninety-one children received CQ/SP and 406 received co-
artemether. Baseline characteristics of these 497 enrolments
are presented in Table 1. Two children enrolled and treated
in the CQ/SP group, and six in the co-artemether group, were
found to have zero parasitaemia upon subsequent examina-
tion of Giemsa-stained duplicate slides. Similarly, four (4.4%)
of the CQ/SP group and 26 (6.5%) of the co-artemether
group were found to have been carrying peripheral
gametocytes at presentation that had not been identiﬁed in
the recruitment clinic. These and all other subjects rando-
mised between treatments were retained in the primary
analysis under our intention-to-treat protocol. Eighty-eight
(96.7%) of the CQ/SP group, and 379 (93.4%) of the co-
artemether group, were visited ﬁve times by a ﬁeld assistant
in the 56 h following recruitment, and received the full
regimen allotted under supervision. Seventy-two (79.1%) and
347 (85.5%) of the CQ/SP and co-artemether groups,
respectively, completed follow-up to day 28, although 12
and 46 of these, respectively, skipped day 7, day 14, or both. A
proﬁle of the study is given in Figure 1.
Adverse Advents
No serious adverse events occurred in either treatment
group, and there were no deaths among children recruited
into the study. Minor complaints noted at the day 7
laboratory visit included headache (12% and 11% in the
CQ/SP and co-artemether groups, respectively), anorexia
Table 1. Baseline Characteristics of Enrolled Patients
Characteristic CQ/SP
(n = 91)
Co-Artemether
(n = 406)
Mean age in years (95% CI) 4.37 (3.81–4.94) 4.40 (4.14–4.66)
Asexual parasitaemia per ll
of blood (interquartile range)
55,203 (15,500–90,000) 56,689 (10,500–87,500)
Mean packed cell volume,
%( 9 5 %C I )
31.7 (30.6–32.7) 31.4 (30.9–31.9)
Mean axillary temperature
on presentation, 8C( 9 5 %C I )
37.7 (37.4–37.9) 37.7 (37.6–37.8)
Proportion found post hoc
with gametocytes
a (95% CI)
4.39% (0.10–8.69%) 6.48% (4.06–8.90%)
a Samples containing at least five per ll of peripheral blood.
DOI: 10.1371/journal.pmed.0020092.t001
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and 5%), and pruritis (1% and 1%).
Gametocyte Prevalence and Density
Children treated with co-artemether were signiﬁcantly less
likely to carry gametocytes during follow-up than children
treated with CQ/SP (Figure 2; p , 0.001 at each of days 7, 14,
and 28). In the CQ/SP group, 42 of 86 (48.8%) evaluable
children had detectable peripheral gametocytaemia at some
point over 28 d of post-treatment follow-up, compared to 30
of 378 (7.9%) evaluable children in the co-artemether group
(relative risk 6.15; 95% CI, 4.10–9.23; p , 0.001). The mean
duration of gametocyte carriage was also signiﬁcantly lower
in the co-artemether group (0.3 d compared to 4.2 d in the
CQ/SP group; range in both groups 2.5–23.5 d; p , 0.0001).
The ratio of mean peripheral gametocyte density in all
children at each follow-up visit is presented in Table 2. Six of
the eight children in the co-artemether group who were
gametocyte-positive at day 28 also harboured trophozoites,
suggesting a new infection emerging from the liver, whereas
only one of 15 gametocyte carriers in the CQ/SP group also
harboured trophozoites at day 28 (odds ratio = 42; 95% CI,
2.4–2,061; Fisher’s exact p = 0.002).
Figure 1. Profile of the Study
Ten and 38 children in the CQ/SP and co-artemether groups, respectively, who were not seen on day 7 were seen on day 14. Two and four
children, respectively, who were not seen on day 7 or day 14 were seen on day 28. Ten children in the co-artemether group not seen on day 14
were seen on day 28.
DOI: 10.1371/journal.pmed.0020092.g001
Figure 2. Gametocyte Carriage after Treatment with CQ/SP or Co-
Artemether
Point-prevalence of gametocyte-positive thick ﬁlms in both treat-
ment groups at 7, 14, and 28 d post-treatment (limit of detection: ﬁve
gametocytes per ll of peripheral blood). Error bars represent 95% CI
calculated from the binomial distribution. Denominators for CQ/SP
and co-artemether (CoArt) groups are, respectively, 74 and 336 (day
7), 79 and 356 (day 14), and 72 and 355 (day 28).
DOI: 10.1371/journal.pmed.0020092.g002
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399 children were seen at the MRC laboratories on day 7, 73
intheCQ/SPgroupand326intheco-artemethergroup.There
were 27 children (37.0%) in the CQ/SP group and 16 children
(4.9%) in the co-artemether group identiﬁed as gametocyte
carriers by our rapid screening procedure (p , 0.001).
Subsequent deﬁnitive microscopy with the Giemsa-stained
duplicatethickﬁlmsgavegoodconcordancewiththescreening
result (positive predictive value 90.2%; speciﬁcity 98.8%).
Explicit consent for venous blood donation for membrane-
feedingofmosquitoeswasobtainedfrom29(67.4%)ofthese43
children: 19 (67.9%) of the gametocyte positives in the CQ/SP
group and 10 (62.5%) of those in the co-artemether group.
Meanagesamongthese29childrenwere3.3years(95%CI,2.4–
4.3) and 4.2 years (2.7–5.7) in the two treatment groups,
respectively.
Results of the transmission experiments are given in
Table 3. Whereas seven children (36.9%) among the CQ/SP
gametocyte donors were infectious to mosquitoes, none of
the gametocyte donors in the co-artemether group was
infectious. The infectious proportion observed in the CQ/
SP group was higher than expected from an earlier study in
which 20% of CQ/SP treated children were infectious,
perhaps due to the use here of an established blood-fed
mosquito colony, which leads to better insect survival. In the
current study, we dissected an average of 18.6 mosquitoes
(95% CI, 16.8–20.4) per infection experiment, compared to
14.8 mosquitoes (95% CI, 12.5–17.1; two-tailed p = 0.021) in a
similar study performed in 2001 that used F1 progeny of wild-
caught female Anopheles. The data in Table 3 show that
gametocyte donors in the co-artemether group carried fewer
gametocytes, and were as a result signiﬁcantly less infectious
than those in the CQ/SP group, consistent with previous
studies [6,10]
Clinical and Parasitological Efficacy of CQ/SP and Co-
Artemether
Among eligible children both regimens employed were
highly efﬁcacious against acute uncomplicated falciparum
malaria. Clinical treatment failure, deﬁned as the persis-
tence or recurrence of malaria symptoms with detectable
peripheral trophozoites, occurred in 8 cases (1.6%), all of
which were in the co-artemether treatment group. One of
these patients received only a single observed dose of co-
artemether at the recruiting clinic, the other seven cases
received the full six-dose regimen under supervision. All
eight clinical failures occurred 2 wk or more after treat-
ment. The cumulative 28-d clinical failure rate among
children under 5 years of age was 2.55%, and among those
5 years and over 0.45%; (relative risk 5.65; 95% CI, 0.70–
45.6; one-sided Fisher’s exact p = 0.064). Parasitological
treatment failure, deﬁned as carriage of asexual parasites
(trophozoites) during post-treatment follow-up, occurred in
fewer than 5% of patients in both treatment groups up to
day 14, but rose to approximately 12% in both groups by
day 28 (Figure 3).
Interpretable PCR data were obtained for 44 of the 60
post-treatment asexual parasite infections identiﬁed by
microscopy. Parasites harboured at the time of treatment
failure were indistinguishable from pre-treatment parasites
by msp2 PCR genotyping in 15 of the 44 cases for which the
data were interpretable. Post-treatment parasites in ﬁve of
the nine children in the CQ/SP group were caused by
recrudescent infections compared to ten of 35 in the co-
artemether group. After correction of the 28-d cumulative
parasitological failure rate using these ratios, it was
estimated that co-artemether was 96.1% efﬁcacious over
28 d, resulting in a total of 14 recrudescent infections,
compared to 91.1% for CQ/SP, resulting in seven recrudes-
cent infections (odds ratio = 0.413; 95% CI, 0.150–1.26; p =
0.058).
Discussion
Co-artemether, administered to children with uncompli-
cated falciparum malaria as a six-dose regimen, is highly
Table 2. Ratio of Means of Gametocyte Density in Peripheral
Blood after Treatment with CQ/SP or Co-Artemether
Day
Post-treatment
n Ratio of Means
CQ/SP:Co-Artemether
95% CI p-Value
Day 7 410 43.1 9.48–196 , 0.01
Day 14 435 117 24.6–552 , 0.01
Day 28 427 1.36 0.100–18.4 0.82
The ratio of arithmetic mean of gametocyte numbers per ll of peripheral blood from both treatment groups at 7,
14, and 28 d post-treatment. Denominators are as in Figure 2.
DOI: 10.1371/journal.pmed.0020092.t002
Table 3. Profile of 29 Children Who Donated Gametocyte-Positive Blood at Day 7 and Results of Transmission Experiments
Characteristic CQ/SP Co-Artemether Difference between Arms (95% CI), p-Value
Number of gametocyte donors, n 19 10 —
Mean day 7 PCV (%) (95% CI) 26.6 26.7 Mean difference 0.121 (5.4 to 5.6), p = 0.96
a
Mean day 7 gametocyte density (ll
1) (Range) 191.6 (0–957.5) 43.25 (2.5–180) Mean ratio 0.148 (0.055–0.402), p , 0.001
b
Number of donors infecting at least one mosquito (%) (95% CI) 7 (36.9%) (13–61%) 0 (0%) (0–31%) Odds ratio 0.0 (0–0.76), p =0 . 0 3 2
c
Proportion of mosquitoes infected (frequency/n) 4.1% (14/345) 0.0% (0/195) Difference in proportions 4.1% (1.4–6.9), p , 0.001
d
Mean oocyst count per dissected mosquito (range) 0.104 (0–10) 0 (0–0) —
e
a Student’s t-test, two-sided
b Ratio of arithmetic means (95% CI); significance tested by negative binomial regression
c Fisher’s exact test of equal proportions, one-sided
d Bootstrap (50,000 replicates)
e Negative binomial regression is not informative with one mean at zero
DOI: 10.1371/journal.pmed.0020092.t003
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gametocyte carriage, the density of peripheral gametocytae-
mia among carriers, and the infectiousness to mosquitoes of
carriers at day 7 compared to a combination of CQ and SP.
In the co-artemether group, none of the ten children who
carried gametocytes at day 7 and donated blood for
membrane-feeding of mosquitoes was found to be infectious.
In contrast, 7 (36.9%) of the 19 gametocyte donors in the CQ/
SP group were infectious, largely due to a signiﬁcantly higher
gametocyte density than in the co-artemether group. This
suggests that co-artemether has a speciﬁc action against
developing gametocytes, as any gametocytes that appeared
on or before day 7 must have been committed to sexual
differentiation at the time of treatment, because of the
period of 8–10 d of sequestered sexual development that
occurs before gametocytes are detectable in the periphery
[26]. This anti-gametocyte activity is additional to the anti-
trophozoite and anti-schizont effects of co-artemether, which
contribute to the very low gametocyte carriage rates
observed later in follow-up. Importantly, we also found
evidence that post-treatment carriage of both trophozoites
and gametocytes in the co-artemether group, but not the CQ/
SP group, was due mainly to new emergent infections, rather
than recrudescent infections, which suggests that arte-
mether-lumefantrine reduces transmission of recrudescent,
resistant parasites compared to CQ/SP. Genotyping of these
infections at resistance-associated loci is underway to test
this further.
The potential of artemisinin-containing combination
therapies to reduce gametocyte carriage rates, and therefore
transmission of falciparum malaria, was ﬁrst shown by Price
et al. [5]. This study, among refugee camps on the Thailand-
Burma border, showed that deploying the combination of
meﬂoquine with artesunate signiﬁcantly reduced the inci-
dence of malaria cases over a few years in this low-
transmission area where asymptomatic infections are rare
and thus drug pressure is very high. We have extended this
work to a setting in sub-Saharan Africa where transmission is
high and seasonal, asymptomatic infections are common, and
as few as 20% of slide-positive infections are treated [27].
Transmission reduction at the population level through the
treatment of clinical cases with artemisinin-containing
combination therapy is unlikely in this setting, and so our
strategy has been to use membrane-feeding of Anopheles
gambiae mosquitoes to measure the infectiousness of individ-
ual treated children who become gametocyte carriers after
treatment [6,10]. Those children who are carrying gameto-
cytes prior to treatment are likely to become infectious
regardless of the treatment received. We can estimate the
proportion of treated children estimated to be infectious by
multiplying the proportion of gametocyte donors that were
infectious by the prevalence of gametocyte carriage at day 7.
Using the data in Table 3, 0% (95% CI, 0–1.9% ) of children
treated with six doses of co-artemether will be infectious to
mosquitoes at day 7. For CQ/SP, the corresponding estimate
is 15.8% (5.6%–26.0%). We have previously estimated that
the mean infectious proportion in control serum membrane-
feeding experiments for SP plus artesunate (three doses) in
1999 was 4%, and for CQ plus artesunate (three doses) was
also 4% [6,10].
Six doses of co-artemether produced the lowest gametocyte
carriage rates we have seen in 5 years of consecutive
transmission studies in Farafenni [6,10], excluding patients
harbouring gametocytes at day 0. Although 2002 had lower
rainfall than any of the previous 10 years, there were
nevertheless signiﬁcant numbers of gametocyte carriers, many
of them infectious, in the CQ/SP group in this study. From a
public health point of view, the effect of each regimen on all
children presenting for treatment, including gametocyte
carriers, is of interest. In co-artemether-treated children
who had unidentiﬁed circulating gametocytes at recruitment,
seven of 20 (29.2%) carried gametocytes at 7 d, compared to
13 of 312 (4.2%) of those without circulating gametocytes at
the time of treatment (Fisher’s exact test, p , 0.01). This
demonstrates that children presenting with gametocytaemia
at day 0 make a disproportionate contribution to day 7
gametocytaemia. Inclusion, hypothetically, of the 83 non-
recruited gametocyte carriers in addition to the 30 that
were, predicts that only 8% of children in the co-artemether
group would have harboured day 7 gametocytes, compared
to 45% in the CQ/SP group. Co-artemether is thus likely to
be highly effective at reducing post-treatment gametocyte
carriage among children irrespective of gametocytaemia at
presentation.
At day 28, gametocyte carriage in the co-artemether group
was associated with evidence of a new infection recently
emerged from the liver. This was not the case with CQ/SP.
Therefore, at day 28 a signiﬁcant proportion of children
treated with CQ/SP will harbour gametocytes that originated
from the treated clinical infection. These gametocytes and
their asexual progenitors have been under sustained drug
selection, given the elimination half-lives of CQ, des-ethyl-
chloroquine (an active metabolite of CQ), sulphadoxine and
pyrimethamine: 5.9 d, 8.5 d, 10.9 d, and 2.9 d, respectively
when given simultaneously as CQ/SP [28]. CQ continues to be
gradually released back into the circulation from host tissues
for at least 30 d [29]. In contrast, artemether and lumefan-
trine are cleared from the body with terminal elimination
half-lives of 0.8 h and 4.5 d, respectively, after administration
of co-artemether [30]. Thus, parasites detected in co-
artemether-treated children during follow-up have, on
average, experienced a shorter period of selective drug
Figure 3. Crude Parasitological Failure after Treatment with CQ/SP or Co-
Artemether
Point-prevalence of trophozoite-positive thick ﬁlms in both treat-
ment groups at 7, 14, and 28 d post-treatment (limit of detection: ﬁve
trophozoites per ll of peripheral blood). Error bars represent 95% CI
calculated from the binomial distribution. Denominators for CQ/SP
and co-artemether (CoArt) groups are, respectively, 74 and 336 (day
7), 79 and 356 (day 14), and 72 and 355 (day 28).
DOI: 10.1371/journal.pmed.0020092.g003
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lumefantrine is ‘‘unprotected’’ for several days following the
elimination of artemether and its metabolites, and so we
cannot rule out the emergence of resistance to lumefantrine
under widespread use of co-artemether.
We found that co-artemether is better than CQ/SP at
preventing recrudescence of treated parasites. However, as
seen with artemisinins in other areas of moderate to high
malaria transmission, co-artemether has the disadvantage of
permitting rapid re-infection, which can lead to new clinical
attacks. This is due to absence of the prophylactic effect
afforded by a pharmacological ‘‘tail,’’ such as that seen with
both SP and CQ. From our co-artemether data, the 28 d new
infection rate in our study population is approximately 10%
with fewer than a ﬁfth of these experiencing a new clinical
attack. Although this reinfection/clinical infection rate may
be even higher in other settings, we believe it would be offset
by the ability of co-artemether to reduce selection and
transmission of drug resistant parasites, and thus make
possible sustainable improvements in both therapeutic and
public health outcomes. In contrast, as our data show, the
pharmacological persistence of CQ and SP eliminates
sensitive parasites emerging from the liver, and so permits a
much smaller proportion of new infections (3.5%). We
predict that CQ/SP thus selects for any resistant mutants
present in the starting population, leading to increased
onward transmission of resistant parasites, and reduced
onward transmission of sensitive parasites.
There are difﬁculties with the introduction of co-arte-
mether as a ﬁrst-line treatment for malaria in Africa. Firstly,
as the six-dose regimen is the most likely to provide the
treatment and transmission-reducing beneﬁts needed, there
may be problems with treatment compliance. Secondly, the
requirement of oily food for adequate absorption may lead to
inadequate drug levels in the blood of many treated
individuals. Effectiveness studies that examine these indica-
tors under conditions as close as possible to the normal
clinical setting, and with both therapeutic and transmission
endpoints, are thus of great importance. Nevertheless, the
therapeutic success of co-artemether as a front-line treat-
ment policy has been demonstrated in KwaZulu–Natal, South
Africa, where it replaced SP [31]. The impact of this policy on
post-treatment transmission in this region is yet to be
determined.
We have shown that, compared to CQ/SP, co-artemether
signiﬁcantly reduces post-treatment gametocyte carriage,
peripheral gametocyte density and infectiousness of game-
tocyte carriers. There is little recrudescence of parasites
under co-artemether, and the majority of gametocyte carriers
are associated with new infections that will have been subject
to little or no drug pressure. We are not suggesting that
introduction of co-artemether as ﬁrst-line treatment policy
in The Gambia or elsewhere is likely to reduce overall
transmission of P. falciparum within the community, but
rather that selective transmission of resistant parasites in
treated patients would be greatly reduced. The beneﬁt is
because drug pressure is exerted only on these treated
infections. Therefore, the use of co-artemether is likely to
have measurable public health beneﬁts in reducing the
impact of drug resistance. We predict that these beneﬁts
would prove far more robust than those transiently enjoyed
after the initial deployment of SP in Africa.
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Patient summary
Background Treatment studies of malaria often focus on the whether
parasites have become resistant to anti-malarial treatment. However, an
ideal treatment would be one that not only cured the patient but also
prevented further transmission of the parasite, especially those that
carry resistance, to mosquitoes and hence to other individuals.
What Did the Researchers Do? They randomised 497 children with
uncomplicated falciparum malaria (the most serious kind) in Gambia to
either a combination of two drugs (chloroquine and sulphadoxine-
pyrimethamine [CQ/SP]) to which many malarial parasites have become
resistant, or a new drug, artemether, in fixed combination with
lumefantrine (co-artemether, brand names Coartem and Riamet). Within
the 4 weeks following treatment they found that patients treated with
co-artemether were much less likely to contain the stage of the malarial
parasite that is infectious, that they carried the parasites for a shorter
time, and that blood from the children treated with co-artemether was
less able to infect mosquitoes.
What Do These Findings Mean? The new combination substantially
reduces the chances of malaria being transmitted from infected patients,
and this finding should be taken into account when deciding which
drugs are the preferred choice for treatment.
Where Can I Get More Information? The Wellcome Trust has
information on malaria: http://www.wellcome.ac.uk/en/malaria/
The World Health Organisation has a programme called Roll Back
Malaria, which has various initiatives: http://www.who.int/topics/
malaria/en/
The Gates foundation funds research on malaria, one arm of which is
the Gates Malaria Partnership: http://www.lshtm.ac.uk/gmp/
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